Necuparanib: Development discontinued
Momenta discontinued its necuparanib program after confirming the results of an independent DSMB’s interim futility analysis and reviewing the unblinded safety and efficacy data from a double-blind, placebo-controlled, North American Phase I/II trial evaluating once-daily...